BiotechFeatured

U.S. Senator Richard Blumenthal Visited NanoViricides Inc. for Update on Coronavirus Drug Development Efforts

SHELTON, CONNECTICUT —  April 6, 2020 — NanoViricides, Inc. (NYSE American: NNVC) (the “Company”) a leader in the development of highly effective antiviral drugs based on a novel, patented, nanomedicines platform, reports that U.S. Senator Richard Blumenthal visited the Company’s facility in Shelton, Connecticut, on Tuesday, March 31, 2020.  

The Honorable Senator Blumenthal visited the Company to receive an update regarding the coronavirus drug development program and to tour the cGMP-capable manufacturing facility. The Senator, his staff, and members of the Press participated in a tour of the Company’s lab and manufacturing facility. 

Following the tour, the Senator held a press conference in front of the building. “NanoViricides, Inc. must be given full and fair consideration for CARES funding because every approach that has strong potential for developing a treatment for COVID-19 must be supported immediately – it will save American lives. I am going to ask my staff in Washington, DC to do whatever we can to enable the Company to access such funding and I will do everything in my power to help NanoViricides get the attention and review they merit from BARDA, the FDA and other federal agencies,” assured Senator Blumenthal.

Anil R. Diwan, PhD, President and Executive Chairman of the Company, welcomed the Senator and gave a brief overview of the Company’s approach to coronavirus drug development to the Press. “We are developing what is effectively a ‘Venus-Fly-Trap’ for the virus particle. Just as a fly is attracted to a Venus-Fly-Trap flower, and then the flower closes onto it, our material attracts the virus particle, and then wraps around the virus particle thereby rendering the virus particle incapable of infecting cells,” said Dr. Diwan, adding, “Our material, i.e., a nanoviricide, mimics the human cell surface receptors to attract the virus.”

“The beauty of this technology is that, a virus would not be able to escape a nanoviricide by mutations or genomic changes, because no matter how much it changes, the mutated virus still lands on the same cellular receptor in the same fashion as its earlier version,” elaborated Ms. Meeta R. Vyas, SB, MBA, the Chief Financial Officer of the Company. “I co-authored the $8.3 Billion CARES act to support the development of drugs, diagnostics, vaccines, and other measures to combat COVID-19,” said Senator Blumenthal, adding, “The drug development by NanoViricides deserves to be supported.”

In response to questions from reporters, Dr. Diwan explained that the Company had already identified some drug candidates that had strong activity against at least two coronaviruses that use different cellular receptors. One of these viruses uses the same receptor, namely ACE2 (angiotensin-converting enzyme 2), as SARS-CoV-2, the coronavirus that causes COVID-19 disease. This broad-spectrum activity provides confidence that these candidates would be effective against SARS-CoV-2, he emphasized. Testing against SARS-CoV-2 itself is expected to be performed very soon.  The Company is in the process of setting up collaborations with external BSL3/BSL4 labs that have developed assays for such testing, he added. Dr. Diwan also stated that the Company intends to publish its results once the verification experiments are completed. In parallel, the Company has already begun certain animal studies to help identify clinical drug candidates against SARS-CoV-2, in order to expedite the program. 

When asked to comment on other drugs being considered to treat the virus, Dr. Diwan explained that the nanoviricides technology was complementary to other drugs because nanoviricides attack the virus outside the cell to prevent it from infecting the cell, while other drugs (except antibodies) work inside the cell to reduce virus replication. “A nanoviricide drug for attacking the virus particle and stopping the re-infection cycle taken together with another drug for limiting viral replication inside cells would make an even more effective treatment for COVID-19 than either one by itself,” he explained. 

“We can produce sufficient quantities of a drug to treat as many as a thousand patients in a single batch in our cGMP-compliant manufacturing facility,” said Dr. Diwan, in response to a question from a reporter regarding manufacturing capacity of the Company adding, “The manufacturing capacity can be substantially increased with additional resources.” 

“We have been working on this project with limited internal resources while continuing our work on our lead drug against Shingles which is close to an IND,” said Dr. Diwan. He added, “At this stage, we need help from government agencies, laboratories, and collaborators to quickly deliver our promising potential treatment to patients suffering from COVID-19. It is an honor to have Senator Blumenthal visit our facility. We are grateful for his commitment to assist us in accessing potential federal funding and agency support, from the likes of the Biomedical Advanced Research and Development Authority (BARDA), the FDA and the NIH, in our effort to save American lives in the fierce battle our country faces to defeat SARS-CoV-2.”

Show More

Related Articles

Back to top button
Close